Evidence map›Paper›PMID 28587834›Full record

ArticleEBioMedicine2017

Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity.

Carol Chen-Scarabelli, Giovanni Corsetti, Evasio Pasini, Francesco S Dioguardi, Gagan Sahni, Jagat Narula, Mara Gavazzoni, Hemang Patel, Louis Saravolatz, Richard Knight and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Carol Chen-ScarabelliDivision of Cardiology, Hunter Holmes McGuire Veterans Affairs Medical Center (VAMC), Richmond, VA, USA; Center for Heart and Vessel Preclinical Studies, St. John Hospital and Medical Center, Wayne State University Medical School, Detroit, MI, USA.
Giovanni CorsettiDepartment of Clinical & Experimental Sciences, Division of Human Anatomy and Physiopathology, University of Brescia, Brescia, Italy.
Evasio PasiniIstituti Clinici Scientifici Maugeri, IRCCS, Cardiac Rehabilitation Division, Lumezzane, Brescia, Italy.
Francesco S DioguardiDepartment of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
Gagan SahniThe Mount Sinai Hospital, Icahn School of Medicine, NY, New York, USA.
Jagat NarulaThe Mount Sinai Hospital, Icahn School of Medicine, NY, New York, USA.
Mara GavazzoniCardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Italy.
Hemang PatelCenter for Heart and Vessel Preclinical Studies, St. John Hospital and Medical Center, Wayne State University Medical School, Detroit, MI, USA.
Louis SaravolatzCenter for Heart and Vessel Preclinical Studies, St. John Hospital and Medical Center, Wayne State University Medical School, Detroit, MI, USA.
Richard KnightCenter for Heart and Vessel Preclinical Studies, St. John Hospital and Medical Center, Wayne State University Medical School, Detroit, MI, USA.
Riccardo RaddinoCardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Italy.
Tiziano M ScarabelliDivision of Cardiology, Pauley Heart Center, Virginia Commonwealth University (VCU) Medical Center, Richmond, VA, USA. Electronic address: tiziano.scarabelli@vcuhealth.org.
University of Brescia · ITMount Sinai Hospital · USSt. John Hospital & Medical Center · USHunter Holmes McGuire VA Medical Center · USIstituti Clinici Scientifici Maugeri · ITUniversity of Milan · ITVirginia Commonwealth University Medical Center · USWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCarfilzomib (CFZ) is a new proteasome inhibitor used for the treatment of multiple myeloma. Besides heart failure, angina and myocardial ischemia occurred following administration of CFZ, which is not contraindicated in patients with recent myocardial infarction/unstable angina excluded from the safety trials. AIM OF STUDY: To test the effects of CFZ (10 METHODS AND

resultsCFZ administered by bolus injection to the isolated heart increased coronary perfusion pressure (CPP) at all tested concentrations and mildly raised left ventricular pressure and heart rate, only at the highest concentration. Addition of CFZ directly into the organ bath increased the basal tone of isolated aortic strips with contraction plateau reached after 10min. This spasmogenic effect doubled following ablation of the endothelium. Pretreatment with CFZ amplified the vasospastic action exerted by KCl, noradrenaline (NA) and angiotensin II (A) on aortic strips, and impaired vasodilation following administration of nitroglycerin (NTG) and nifedipine (NFP) on the contraction plateau induced by KCl, NA and A. Aortic strips pretreated with CFZ exhibited impaired relaxation, as compared to untreated strips, following administration of acetylcholine (Ach), an endothelium-dependent vasodilating agent, on the plateau of NA contraction (p<0.05).

conclusionsCFZ increased CPP, resting vasoconstricting tone and the spasmogenic effect of different agents. Preincubation with CFZ decreased the anti-spasmogenic activity of NTG and NFP, as well as reduced by over 50% the vasodilating effect of Ach, suggesting that CFZ can impair vasodilation via an endothelium dependent mechanism. Further studies are warranted to establish its clinical safety in patients with known CAD and prior history of coronary spasm.

Indexed as

AcetylcholineAnimalsArterial PressureCoronary VesselsHeart RateNitroglycerinOligopeptidesProteasome InhibitorsRabbitsVascular ResistanceAcetylcholinecarfilzomibNitroglycerinOligopeptidesProteasome InhibitorsCarfilzomibCoronary resistanceMultiple myelomaProteasome inhibitorsVascular tone

Identifiers

PMID28587834
PMCPMC5514385
OpenAlexW2618223593

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.